JPWO2020261205A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020261205A5 JPWO2020261205A5 JP2021576778A JP2021576778A JPWO2020261205A5 JP WO2020261205 A5 JPWO2020261205 A5 JP WO2020261205A5 JP 2021576778 A JP2021576778 A JP 2021576778A JP 2021576778 A JP2021576778 A JP 2021576778A JP WO2020261205 A5 JPWO2020261205 A5 JP WO2020261205A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- fluoro
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 229940125708 antidiabetic agent Drugs 0.000 claims 3
- 239000003472 antidiabetic agent Substances 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 3
- 229960003105 metformin Drugs 0.000 claims 3
- GPILESOGMROEGP-UHFFFAOYSA-N BrC=1C2=C(SC=1C(=O)O)C=C(S2)F Chemical compound BrC=1C2=C(SC=1C(=O)O)C=C(S2)F GPILESOGMROEGP-UHFFFAOYSA-N 0.000 claims 2
- UXMBSHHPPVOPJU-UHFFFAOYSA-N ClC=1C2=C(SC=1C(=O)O)C=C(S2)F Chemical compound ClC=1C2=C(SC=1C(=O)O)C=C(S2)F UXMBSHHPPVOPJU-UHFFFAOYSA-N 0.000 claims 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 208000035180 MODY Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- -1 chloro, fluoro, methyl Chemical group 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000002792 enkephalinase inhibitor Substances 0.000 claims 2
- 239000000859 incretin Substances 0.000 claims 2
- 201000006950 maturity-onset diabetes of the young Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- VYLOOGHLKSNNEK-JWTNVVGKSA-N 2-[(1R,5S)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid Chemical compound C([C@]1(CC[C@@](C2)(N1C=1SC3=CC(=CC(F)=C3N=1)C(O)=O)[H])[H])C2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F VYLOOGHLKSNNEK-JWTNVVGKSA-N 0.000 claims 1
- UKBQFBRPXKGJPY-INIZCTEOSA-N 2-[5-(3-ethoxypyridin-2-yl)oxypyridin-3-yl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide Chemical compound C(C)OC=1C(=NC=CC=1)OC=1C=C(C=NC=1)C1=NC=C(C=N1)C(=O)N[C@@H]1COCC1 UKBQFBRPXKGJPY-INIZCTEOSA-N 0.000 claims 1
- HYBAKUMPISVZQP-DEOSSOPVSA-N 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]pyridin-2-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid Chemical compound C(#N)C1=CC(=C(COC2=CC=CC(=N2)C2CCN(CC2)CC2=NC3=C(N2C[C@H]2OCC2)C=C(C=C3)C(=O)O)C=C1)F HYBAKUMPISVZQP-DEOSSOPVSA-N 0.000 claims 1
- LXZMHBHEXAELHH-UHFFFAOYSA-N 4-[6-methoxy-4-(7-oxo-1-propan-2-ylspiro[4,6-dihydroindazole-5,4'-piperidine]-1'-carbonyl)pyridin-2-yl]benzoic acid Chemical compound N=1C(OC)=CC(C(=O)N2CCC3(CC2)CC(=O)C=2N(C(C)C)N=CC=2C3)=CC=1C1=CC=C(C(O)=O)C=C1 LXZMHBHEXAELHH-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 229940127194 DGAT2 inhibitor Drugs 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 claims 1
- KJYARKWOFQCHIX-UHFFFAOYSA-N FC(C=1C2=C(SC=1C(=O)O)C=C(S2)F)F Chemical compound FC(C=1C2=C(SC=1C(=O)O)C=C(S2)F)F KJYARKWOFQCHIX-UHFFFAOYSA-N 0.000 claims 1
- YELALAJPIPNYDH-UHFFFAOYSA-N FC1=C(C=2SC(=CC=2S1)C(=O)O)F Chemical compound FC1=C(C=2SC(=CC=2S1)C(=O)O)F YELALAJPIPNYDH-UHFFFAOYSA-N 0.000 claims 1
- AGOZEKLCZKRWHH-UHFFFAOYSA-N FC=1C2=C(SC=1C(=O)O)C=C(S2)F Chemical compound FC=1C2=C(SC=1C(=O)O)C=C(S2)F AGOZEKLCZKRWHH-UHFFFAOYSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000003790 Foot Ulcer Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 208000030162 Maple syrup disease Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000027032 Renal vascular disease Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 201000004202 endocervical carcinoma Diseases 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 208000037828 epithelial carcinoma Diseases 0.000 claims 1
- 229950006535 ertugliflozin Drugs 0.000 claims 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 208000018914 glucose metabolism disease Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 230000004140 ketosis Effects 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 208000024393 maple syrup urine disease Diseases 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 208000015670 renal artery disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 229960004034 sitagliptin Drugs 0.000 claims 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868057P | 2019-06-28 | 2019-06-28 | |
| US62/868,057 | 2019-06-28 | ||
| US202062960817P | 2020-01-14 | 2020-01-14 | |
| US62/960,817 | 2020-01-14 | ||
| US202063031719P | 2020-05-29 | 2020-05-29 | |
| US63/031,719 | 2020-05-29 | ||
| PCT/IB2020/056066 WO2020261205A1 (en) | 2019-06-28 | 2020-06-26 | Thieno[3,2-b]thiophene-2-carboxylic acid compounds having bckdk inhibiting activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540000A JP2022540000A (ja) | 2022-09-14 |
| JP2022540000A5 JP2022540000A5 (https=) | 2023-06-02 |
| JPWO2020261205A5 true JPWO2020261205A5 (https=) | 2023-06-02 |
Family
ID=71452516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021576778A Pending JP2022540000A (ja) | 2019-06-28 | 2020-06-26 | Ｂｃｋｄｋ阻害活性を有するチエノ［３，２－ｂ］チオフェン－２－カルボン酸化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11542270B2 (https=) |
| EP (1) | EP3990461A1 (https=) |
| JP (1) | JP2022540000A (https=) |
| CA (1) | CA3144869C (https=) |
| PY (1) | PY2030111A (https=) |
| TW (1) | TW202115086A (https=) |
| UY (1) | UY38768A (https=) |
| WO (1) | WO2020261205A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| TW202228762A (zh) * | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| WO2022161915A1 (en) * | 2021-01-27 | 2022-08-04 | Koninklijke Philips N.V. | Apparatus and method for augmented interpretation of magnetic resonance and ultrasound shear wave elastography for monitoring liver fibrosis |
| EP4294812A4 (en) * | 2021-02-21 | 2025-03-26 | Ramino-Bio Ltd. | Thiophene based compounds and use thereof as bckdk inhibitors |
| US12605702B2 (en) | 2021-04-26 | 2026-04-21 | Reprieve Cardiovascular, Inc. | Measuring and/or detecting analytes in urine, and associated systems, devices, and methods |
| JP2024526669A (ja) * | 2021-07-12 | 2024-07-19 | リプリーヴ カーディオヴァスキュラー インコーポレイテッド | 推定過剰流体に基づく流体療法及び関連のシステム及び方法 |
| CR20240183A (es) * | 2021-12-01 | 2024-06-07 | Pfizer | Inhibidores y/o degradadores de bckdk |
| CN114903994A (zh) * | 2022-04-19 | 2022-08-16 | 上海交通大学医学院附属瑞金医院 | Bckdk作为靶点在制备2型糖尿病药物中的应用 |
| EP4695226A1 (en) | 2023-04-14 | 2026-02-18 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| US12471842B2 (en) | 2023-09-12 | 2025-11-18 | Reprieve Cardiovascular, Inc. | Fluid therapy based on adjusted urine output rate, and associated systems, devices, and methods |
| WO2025153045A1 (zh) * | 2024-01-18 | 2025-07-24 | 上海拓界生物医药科技有限公司 | 一种吡啶并噻吩-2-羧酸衍生物及其制备方法和用途 |
| TW202539633A (zh) | 2024-02-01 | 2025-10-16 | 美商輝瑞股份有限公司 | 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途 |
| WO2025175244A1 (en) | 2024-02-16 | 2025-08-21 | Reprieve Cardiovascular, Inc. | Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods |
| US20250326741A1 (en) | 2024-04-22 | 2025-10-23 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026013531A1 (en) | 2024-07-10 | 2026-01-15 | Pfizer Inc. | Spiro[2.5]octane compounds |
| WO2026033382A1 (en) | 2024-08-07 | 2026-02-12 | Pfizer Inc. | Heterocyclic glp-1r modulators |
| WO2026042018A1 (en) | 2024-08-21 | 2026-02-26 | Pfizer Inc. | 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes |
| WO2026078617A1 (en) | 2024-10-11 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078674A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078672A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
| WO2026078671A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078670A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists |
| WO2026078673A1 (en) | 2024-10-13 | 2026-04-16 | Pfizer Inc. | Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| WO2000001389A1 (en) | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| DZ3347A1 (fr) * | 2000-05-22 | 2001-11-29 | Aventis Pharma Inc | Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| KR100869616B1 (ko) | 2004-05-12 | 2008-11-21 | 화이자 프로덕츠 인코포레이티드 | 프롤린 유도체 및 그의 다이펩티딜 펩티다제－ｉｖ저해제로서의 용도 |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| CA2659060A1 (en) * | 2006-06-30 | 2008-01-10 | Sepracor Inc. | Fused heterocyclic inhibitors of d-amino acid oxidase |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| MY155418A (en) | 2008-08-28 | 2015-10-15 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| US20110319379A1 (en) | 2009-03-11 | 2011-12-29 | Corbett Jeffrey W | Substituted Indazole Amides And Their Use As Glucokinase Activators |
| MY151246A (en) | 2009-03-11 | 2014-04-30 | Pfizer | Benzofuranyl derivatives |
| WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
| NZ596467A (en) | 2009-06-05 | 2014-01-31 | Pfizer | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| EP2954780A1 (en) | 2009-07-24 | 2015-12-16 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| US20120022116A1 (en) | 2010-07-20 | 2012-01-26 | Huayun Deng | Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex |
| EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| PE20191817A1 (es) | 2017-05-11 | 2019-12-27 | Bristol Myers Squibb Co | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
| TW202115086A (zh) * | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
-
2020
- 2020-06-24 TW TW109121446A patent/TW202115086A/zh unknown
- 2020-06-26 US US16/912,828 patent/US11542270B2/en active Active
- 2020-06-26 PY PY202002030111A patent/PY2030111A/es unknown
- 2020-06-26 EP EP20736441.5A patent/EP3990461A1/en active Pending
- 2020-06-26 JP JP2021576778A patent/JP2022540000A/ja active Pending
- 2020-06-26 WO PCT/IB2020/056066 patent/WO2020261205A1/en not_active Ceased
- 2020-06-26 UY UY0001038768A patent/UY38768A/es not_active Application Discontinuation
- 2020-06-26 CA CA3144869A patent/CA3144869C/en active Active
- 2020-10-23 US US17/078,257 patent/US11059833B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020261205A5 (https=) | ||
| JP2021535126A5 (https=) | ||
| CN101903356B (zh) | 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用 | |
| ES2536319T3 (es) | Compuestos bicíclicos como inhibidores de acetil-CoA carboxilasa (ACC) | |
| KR101345316B1 (ko) | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 | |
| US8569339B2 (en) | Soluble guanylate cyclase activators | |
| US20200347016A1 (en) | Substituted pyrrolidines as g-protein coupled receptor 43 agonists | |
| JPWO2020044266A5 (https=) | ||
| JP7217273B6 (ja) | ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用 | |
| US8791146B2 (en) | 2-alkoxy-substituted dicyanopyridines and their use | |
| US10214521B2 (en) | Fused heterocyclic compounds as GPR120 agonists | |
| US9150575B2 (en) | Piperidinylpyrazolopyridine derivative | |
| JP5301456B2 (ja) | ヘテロアリールオキシキナゾリン誘導体 | |
| US20100190980A1 (en) | Pyrazinamide compound | |
| JP2020521730A5 (https=) | ||
| CN114728168A (zh) | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 | |
| JP2011502982A5 (https=) | ||
| JP2017515836A5 (https=) | ||
| US9340506B2 (en) | Acetamide derivatives as glucokinase activators, their process and medicinal applications | |
| JP2020534263A (ja) | 高血糖症の治療で使用するためのヘテロアリール置換されたベータ−ヒドロキシエチルアミン | |
| CN102295637A (zh) | 5-脂氧合酶活化蛋白(flap)抑制剂 | |
| JPWO2009081782A1 (ja) | Ｎ−ピラゾール−２−ピリジンカルボキサミド誘導体 | |
| WO2012129967A1 (zh) | 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 | |
| JPWO2020261144A5 (https=) | ||
| RU2024114883A (ru) | Производные 3-фенил-1-бензотиофен-2-карбоновой кислоты в качестве ингибиторов киназы дегидрогеназы альфа-кетокислот с разветвленной цепью для лечения диабета, заболеваний почек, nash и сердечной недостаточности |